Business Context and Reporting Period
This Form 8-K Current Report was filed by Revolution Medicines, Inc. on August 31, 2023. The report addresses corporate governance changes effective September 5, 2023, specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or operational metrics.
Material Changes
- Board Resignation: Eric T. Schmidt, Ph.D., resigned from the Board of Directors and the Audit Committee, effective September 5, 2023.
- Reason for Departure: The resignation was due to Dr. Schmidt's acceptance of a position as an investment analyst. The Company states this was not a result of any disagreement with the Company or its operations.
- Board Appointments:
- Lorence Kim, M.D., was appointed Chair of the Audit Committee.
- Alexis Borisy was appointed as a member of the Audit Committee to fill the vacancy left by Dr. Schmidt.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document contains no discussion of contingencies or unusual items beyond the standard disclosure of the director's departure.
Key Facts for Investor Verification
- Confirm the effective date of Eric T. Schmidt's resignation (September 5, 2023).
- Verify the new composition of the Audit Committee, specifically the appointment of Lorence Kim as Chair and Alexis Borisy as a member.
- Review the Company's subsequent filings to ensure no undisclosed disagreements or operational impacts resulted from the Board change.